Efficacy and safety of heterologous booster vaccination with Ad26.COV2.S after BNT162b2 mRNA COVID‐19 vaccine in haemato‐oncological patients with no antibody response

SummaryA group of 269 pupils of the Harbour and Transport Training Institute in Rotterdam (group A), aged 13–20 years, and of 109 patients of the Dr Mr Willem van den Bergh Foundation at Noordwijk (group B), aged 11–21 years, were immunized with a whole virus vaccine containing 10, 20, or 40 μg HA of A/USSR/92/77 (H1N1) influenza virus. A booster vaccination was administered 6 weeks later with 20 μg HA of the same virus. Many of the participants had been immunized during the two preceding years with a whole virus vaccine containing A/New Jersey/8/76 (H1N1) (A/NJ/76) virus. The side-effects, mostly of a moderate nature, increased with the dose of virus in the vaccine. In group A side effects were least frequent in the vaccinees who had never received A/NJ/76 vaccine. A single dose of A/USSR/77 vaccine did not produce satisfactory levels of homologous antibodies. After booster immunization with 20 μg HA of A/USSR/77 virus participants showed a higher homologous antibody response in all vaccine-dose groups if they had not been immunized with A/NJ/76 virus in previous years. After primary and especially after booster immunization with A/USSR/77 virus, a very high response against A/NJ/76 virus and adequate levels of A/NJ/76 antibody were found in participants who had been immunized previously with A/NJ/76 virus. Those who had not been immunized with this virus previously showed no or a very low antibody response to A/NJ/76 virus.

Download Full-text

Antibody Response After a Four‐Site Intradermal Booster Vaccination with Cell‐Culture Rabies Vaccine

Clinical Infectious Diseases ◽

10.1086/514737 ◽

1999 ◽

Vol 28 (5) ◽

pp. 1100-1103 ◽

Cited By ~ 26

Author(s):

Terapong Tantawichien ◽

Maneerat Benjavongkulchai ◽

Kornvika Limsuwan ◽

Pakamatz Khawplod ◽

Wilaiwan Kaewchompoo ◽

...

Keyword(s):

Cell Culture ◽

Antibody Response ◽

Booster Vaccination ◽

Rabies Vaccine

Download Full-text

Treatment and secondary prevention of venous thromboembolism in cancer patients

Kardiologiia ◽

10.18087/cardio.2020.3.n904 ◽

2020 ◽

Vol 60 (3) ◽

pp. 71-79

Author(s):

G. A. Shakaryants ◽

D. A. Budanova ◽

K. V. Lobastov ◽

N. V. Khabarova ◽

Yu. Yu. Kirichenko ◽

...

Keyword(s):

Venous Thromboembolism ◽

High Risk ◽

Secondary Prevention ◽

Cancer Patients ◽

Risk Group ◽

High Risk Group ◽

Efficacy And Safety ◽

Thromboembolic Complications ◽

Oncological Patients ◽

Venous Thromboembolic

Oncological patients are a high-risk group for venous thromboembolic complications. These complications significantly impair the outcome of antitumor treatment and take a leading place in the structure of mortality. Treatment of venous thromboembolic complications in oncological patients is a serious challenge. When selecting an anticoagulant, the physician should consider its efficacy and safety and possible drug interactions. Based on results of multiple studies presented in this article, physicians will be able to choose an optimum therapeutic tactics and secondary prevention of thromboembolic complications for this group of patients.

Download Full-text

Control and Preventive Study of Brucellosis by Using

KnE Life Sciences ◽

10.18502/kls.v3i6.1132 ◽

2017 ◽

Vol 3 (6) ◽

pp. 234

Author(s):

Rahmahani J ◽

Handijatno D ◽

Tyaningsih W ◽

Suwarno Suwarno

Keyword(s):

Immune Response ◽

Sodium Chloride ◽

Antibody Response ◽

Brucella Abortus ◽

Cellular Response ◽

Booster Vaccination ◽

Humoral Response ◽

Igg Antibody ◽

Whole Cells ◽

Cellular Immune

The aims of this research is to determine the ability of sub unit lipopolysacharide(LPS) vaccine of Brucella abortus strain S-19 in mice and goat, including IgM and sub classes IgG antibody humoral response, cellular mediated immune response (IL-2, IFN- γ) in mice, also IgG as humoral immunity, IL-4 and IL-12 as cellular immunity, comparison affectivity with Brucella abortus strain RB-51 vaccine in goat . This research has two steps methods. Step first, 30 Balb C mice were divided into 3 groups and vaccinated subcutaneously, First group injectedB. abortus S-19, second group injected LPS and third group injected sodium chloride solution. Booster vaccination was conducted every two weeks till the eight week after first vaccination. The second step performed vaccinated to 30 goats divided into three groups. First group was injected by subcutaneous LPS 50 µg/ml and second group injected LPS 100 µg/ml and the third group injected with sodium chloride as control. Booster vaccination conducted 2 weeks after first vaccination and second vaccination. Result of the research conferred. Result research, antibody response in mice showed vaccination by LPS of B. abortus S-19 showed higher titer than vaccination by whole cells but inverse cellular response. The both vaccines showed induce subclass antibody response, vaccination by LPS tendency to IgM response but vaccination by Whole cells active vaccine tendency to IgG1, IgG 2a and IgG2b. Response antibody in goat on two weeks after first vaccination, vaccination with LPS of B. abortus S-19, dose 50 µg/ml failed or zero titer IgG response but dose 100 µg/ml was 500response antibody on two weeks after second vaccination by dose 50 µg/ml was 340 but by dose 100 µg/ml was 960, while cellular IL-12 response two weeks after first vaccination by dose 50 µg/ml was 22.88 pg/ml but by 100 µg/ml was 62.15 pg/ml. Response cellular IL -12 two weeks after second vaccination 50 µg/ml was 12.04 pg/ml while by dose100 µg/ml was 130.88pg/ml Cellular immune response IL-4 on two weeks after first vaccination, dose 50 µg/ml showed 55.57 pg/ml but by dose100 µg/ml was 49.35 pg/ ml. Response cellular IL-4 on two weeks after second vaccination by dose 50 µg/ml was 22.17 pg/ml but by dose 100 µg/ml was 143.89 pg/ml Keyword: Vaccine sub-unit LPS of Brucella abortus S-19, Humoral antibody, Cellular antibody

Download Full-text

Booster vaccination with live attenuated Vibrio anguillarum elicits strong protection despite weak specific antibody response in zebrafish

Journal of Applied Ichthyology ◽

10.1111/jai.12358 ◽

2013 ◽

Vol 30 (1) ◽

pp. 117-120 ◽

Cited By ~ 2

Author(s):

Z.-H. Zhang ◽

H.-Z. Wu ◽

J.-F. Xiao ◽

Q.-Y. Wang ◽

Q. Liu ◽

...

Keyword(s):

Antibody Response ◽

Specific Antibody ◽

Vibrio Anguillarum ◽

Booster Vaccination ◽

Specific Antibody Response

Download Full-text

Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies

Cancer Cell ◽

10.1016/j.ccell.2021.09.001 ◽

2021 ◽

Vol 39 (10) ◽

pp. 1297-1299 ◽

Cited By ~ 2

Author(s):

Lee M. Greenberger ◽

Larry A. Saltzman ◽

Jonathon W. Senefeld ◽

Patrick W. Johnson ◽

Louis J. DeGennaro ◽

...

Keyword(s):

Antibody Response ◽

B Cell ◽

Booster Vaccination ◽

Hematologic Malignancies

Download Full-text

Antibody response to booster vaccination with tetanus and diphtheria in adults exposed to perfluorinated alkylates

Journal of Immunotoxicology ◽

10.3109/1547691x.2015.1067259 ◽

2015 ◽

Vol 13 (2) ◽

pp. 270-273 ◽

Cited By ~ 28

Author(s):

Katrine Kielsen ◽

Zaiba Shamim ◽

Lars P. Ryder ◽

Flemming Nielsen ◽

Philippe Grandjean ◽

...

Keyword(s):

Antibody Response ◽

Booster Vaccination

Download Full-text

Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson’s Disease: A Randomized, Placebo-Controlled, Phase 1 Study

Journal of Parkinson s Disease ◽

10.3233/jpd-212594 ◽

2021 ◽

pp. 1-11

Author(s):

Werner Poewe ◽

Dieter Volc ◽

Klaus Seppi ◽

Rossella Medori ◽

Petra Lührs ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Antibody Response ◽

Phase 1 ◽

Booster Vaccination ◽

Active Immunotherapy ◽

Igg Antibody ◽

Phase 1 Study ◽

Positive Antibody ◽

Secondary Objective

Background: Immunotherapies targeting α-synuclein aim to limit its extracellular spread in the brain and prevent progression of pathology in Parkinson’s disease (PD). PD03A is a specific active immunotherapy (SAIT) involving immunization with a short peptide formulation. Objective: This phase 1 study characterized the safety and tolerability of PD03A in patients with early PD. A key secondary objective was to evaluate immunological activity following immunization. Methods: This was a phase 1 study of two different doses of PD03A versus placebo in PD patients. Patients were randomized (1:1:1) to receive four priming plus one booster vaccination of PD03A 15μg, PD03A 75μg or placebo and were followed for 52 weeks. Results: Overall, 36 patients were randomized, of which 35 received five immunizations and completed the study. All patients experienced at least one adverse event. Transient local injection site reactions affected all but two patients; otherwise most AEs were considered unrelated to study treatment. A substantial IgG antibody response against PD03 was observed with a maximum titer achieved at Week-12. Differences in titers between both active groups versus placebo were statistically significant from the second immunization at Week-8 until Week-52. Conclusion: The safety profile and positive antibody response of PD03A supports the further development of active immunotherapeutic approaches for the treatment of PD.

Download Full-text

A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®

Trials ◽

10.1186/s13063-021-05664-0 ◽

2021 ◽

Vol 22 (1) ◽

Author(s):

Benjamin Speich ◽

Frédérique Chammartin ◽

Daniel Smith ◽

Marcel P. Stoeckle ◽

Patrizia Amico ◽

...

Keyword(s):

Cohort Study ◽

Antibody Response ◽

Pilot Trial ◽

Type I ◽

Immunocompromised Patients ◽

Efficacy And Safety ◽

Randomized Controlled ◽

Link Type ◽

Patient Consent ◽

Set Up

Abstract Background Late 2019, a new highly contagious coronavirus SARS-CoV-2 has emerged in Wuhan, China, causing within 2 months a pandemic with the highest disease burden in elderly and people with pre-existing medical conditions. The pandemic has highlighted that new and more flexible clinical trial approaches, such as trial platforms, are needed to assess the efficacy and safety of interventions in a timely manner. The two existing Swiss cohorts of immunocompromised patients (i.e., Swiss HIV Cohort Study (SHCS) and Swiss Transplant Cohort Study (STCS)) are an ideal foundation to set-up a trial platform in Switzerland leveraging routinely collected data. Within a newly founded trial platform, we plan to assess the efficacy of the first two mRNA SARS-CoV-2 vaccines that reached market authorization in Switzerland in the frame of a pilot randomized controlled trial (RCT) while at the same time assessing the functionality of the trial platform. Methods We will conduct a multicenter randomized controlled, open-label, 2-arm sub-study pilot trial of a platform trial nested into two Swiss cohorts. Patients included in the SHCS or the STCS will be eligible for randomization to either receiving the mRNA vaccine Comirnaty® (Pfizer/BioNTech) or the COVID-19 mRNA Vaccine Moderna®. The primary clinical outcome will be change in pan-lg antibody response (pan-Ig anti-S1-RBD; baseline vs. 3 months after first vaccination; binary outcome, considering ≥ 0.8 units/ml as a positive antibody response). The pilot study will also enable us to assess endpoints related to trial conduct feasibility (i.e., duration of RCT set-up; time of patient recruitment; patient consent rate; proportion of missing data). Assuming vaccine reactivity of 90% in both vaccine groups, we power our trial, using a non-inferiority margin such that a 95% two-sided confidence interval excludes a difference in favor of the reference group of more than 10%. A sample size of 380 (190 in each treatment arm) is required for a statistical power of 90% and a type I error of 0.025. The study is funded by the Swiss National Science Foundation (National Research Program NRP 78, “COVID-19”). Discussion This study will provide crucial information about the efficacy and safety of the mRNA SARS-CoV-2 vaccines in HIV patients and organ transplant recipients. Furthermore, this project has the potential to pave the way for further platform trials in Switzerland. Trial registration ClinicalTrials.govNCT04805125. Registered on March 18, 2021

Download Full-text

Efficacy and Safety of Third Dose of the COVID-19 Vaccine among Solid Organ Transplant Recipients: A Systemic Review and Meta-Analysis

Vaccines ◽

10.3390/vaccines10010095 ◽

2022 ◽

Vol 10 (1) ◽

pp. 95

Author(s):

Orly Efros ◽

Roi Anteby ◽

Mirit Halfon ◽

Eshcar Meisel ◽

Eyal Klang ◽

...

Keyword(s):

Antibody Response ◽

Organ Transplant ◽

Vaccine Dose ◽

Solid Organ Transplant ◽

Solid Organ ◽

Efficacy And Safety ◽

Transplant Recipients ◽

Organ Transplant Recipients ◽

The Third ◽

Solid Organ Transplant Recipients

Solid organ transplant recipients were demonstrated to have reduced antibody response to the first and second doses of the COVID-19 mRNA vaccine. This review evaluated published data on the efficacy and safety of the third dose among solid organ transplant recipients. We performed a systematic search of PubMed, EMBASE, and Web of Science to retrieve studies evaluating the efficacy of the third dose of anti-SARS-CoV-2 vaccines in adult solid organ transplant recipients. Serologic response after the third vaccine was pooled using inverse variance and generalized linear mixed and random-effects models. Seven studies met our inclusion criteria. A total of 853 patients received the third dose. Except for one randomized controlled trial, all studies were retrospective in design. Following the third COVID-19 vaccine dose, antibody response occurred in 6.4–69.2% of patients. The pooled proportion of antibody response rate after the third vaccine was 50.3% (95% confidence interval (CI): 37.1–63.5, I2 = 90%). Five papers reported the safety profile. No severe adverse events were observed after the third vaccine dose. In conclusion, a third dose of the SARS-CoV-2 mRNA vaccine in solid organ transplant recipients is associated with improved immunogenicity and appears to be safe. Nevertheless, a significant portion of patients remain seronegative.

Download Full-text